Income StatementBalance SheetCash FlowSegments
KLR

Kailera Therapeutics Cash Flow Statement

Operating, investing, and financing cash movements
Net Cash From Operating-$68.3MNet Cash From Investing$22.8MNet Cash From Financing-$3.0MDepreciation And Amortization Cf$101.0KNet Change In Cash-$48.4M
Market Cap$2.8B

Operating

MetricQ1 '25Q1 '26
Other non-cash income (expense)$7.0K$19.0K
Amortization of Investment Discount and Premium$0.0$1.2M
Accretion (amortization) of discounts and premiums on investments$0.0$1.2M
Other non-cash income (expense)$7.0K$19.0K
Change in accounts payable$645.0K-$495.0K
Change in accrued liabilities$1.1M$9.4M
Change in operating lease liabilities$0.0-$282.0K
Change in other assets$10.0K-$27.0K
Change in other liabilities$0.0-$69.0K
Other working capital changes$7.0K$19.0K
Depreciation and amortization$63.0K$101.0K
Accretion (Amortization) of Investment Discounts and Premiums$0.0$1.2M
Other Non-Cash Income (Expense)$7.0K$19.0K
Other Non-cash Income (Expense)$7.0K$19.0K
Other Non-cash Income (Expense)$7.0K$19.0K
Change in other non-current liabilities$0.0-$69.0K
Net cash from operating activities-$18.2M-$68.3M
Net income-$18.0M-$78.9M
Other non-cash income (expense)$7.0K$19.0K
Accretion (Amortization) of Discounts and Premiums, Investments$0.0$1.2M
Change In Fair Value Of Preferred Stock Tranche Right Liability$800.0K$0.0
Operating lease liabilities$0.0-$282.0K
Other current liabilities$1.1M$9.4M
Other long-term liabilities$0.0-$69.0K
Increase (Decrease) in Prepaid Expense and Other Assets$2.7M-$42.0K
Noncash Lease Income Expense$13.0K-$293.0K
Other Noncash Income (Expense)$7.0K$19.0K
Other Non-cash Income and Expense$7.0K$19.0K
Other Non-Cash Adjustments$7.0K$19.0K
Other Non-Cash Income and Expense$7.0K$19.0K
Accretion (Amortization) of Investment Discounts and Premiums$0.0$1.2M
Stock-based compensation$1.5M$3.9M

Other

MetricQ1 '25Q1 '26
Net Change in Cash Excluding Exchange Rate Effect-$72.6M-$48.4M
Net Change in Cash Excluding FX Effect-$72.6M-$48.4M
Net increase (decrease) in cash-$72.6M-$48.4M
Net Change in Cash Excluding Exchange Rate Effect-$72.6M-$48.4M
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses$0.0$2.1M

Financing

MetricQ1 '25Q1 '26
Payments For Repurchase Of Initial Public Offering$0.0$3.0M
Net cash from financing activities$0.0-$3.0M
Proceeds from issuance of common stock$0.0$57.0K

Investing

MetricQ1 '25Q1 '26
Net cash from investing activities-$54.4M$22.8M